I liked the part about it not being too early to approach potential commercial partners (around 49:30 in the Q&A) when answering a question about things to look forward to in the next 3-6 months. There was also some discussion about the partnership with PyschoGenics in the US as well, and importantly, how they have worked with BP over there to commercialise products. And also important, whilst this was to discuss MDMA inspired therapy, they did drop in the well advanced human trials for cannabinoid treatments, which to me is where EMD has an advantage to become self sustaining by getting a product on shelves to generate revenue streams whilst developing further products without the constant need for CR's.
Should be a good 6-12 months ahead for shareholders, despite the market jitters.
EMD Price at posting:
21.5¢ Sentiment: Buy Disclosure: Held
